Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery  by Stone, David H. et al.
From the Eastern Vascular Society
Clopidogrel is not associated with major bleeding
complications during peripheral arterial surgery
David H. Stone, MD,a Philip P. Goodney, MD,a,b Andres Schanzer, MD,c Brian W. Nolan, MD,a,b
Julie E. Adams, MD,d Richard J. Powell, MD,a Daniel B. Walsh, MD,a and Jack L. Cronenwett, MD,a
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Objectives: Persistent variation in practice surrounds preoperative clopidogrel management at the time of vascular surgery.
While some surgeons preferentially discontinue clopidogrel citing a perceived risk of perioperative bleeding, others will
proceed with surgery in patients taking clopidogrel for an appropriate indication. The purpose of this study was to
determine whether preoperative clopidogrel use was associated with significant bleeding complications during peripheral
arterial surgery.
Methods: We reviewed a prospective regional vascular surgery registry recorded by 66 surgeons from 15 centers in New
England from 2003 to 2009. Preoperative clopidogrel use within 48 hours of surgery was analyzed among patients
undergoing carotid endarterectomy (CEA), lower extremity bypass (LEB), endovascular abdominal aortic aneurysm
repair (EVAR), and open abdominal aortic aneurysm repair (oAAA). Ruptured AAAs were excluded. Endpoints included
postoperative bleeding requiring reoperation, as well as the incidence and volume of blood transfusion. Statistical analysis
was performed using analysis of variance, Fisher exact, 2, and Wilcoxon rank-sum tests.
Results: Over the study interval, a total of 10,406 patients underwent surgery, including 5264 CEA, 2883 LEB, 1125
EVAR, and 1134 oAAA repair. Antiplatelet use among all patients varied, with 19% (n  2010) taking no antiplatelet
agents, 69% (n 7132) taking aspirin (ASA) alone, 2.2% (n 229) taking clopidogrel alone, and 9.7% (n 1017) taking
both ASA and clopidogrel. Clopidogrel alone or as dual antiplatelet therapy was most frequently used prior to CEA and
least frequently prior to oAAA group (CEA 16.1%, LEB 9.0%, EVAR 6.5%, oAAA 5%). Reoperation for bleeding was not
significantly different among patients based on antiplatelet regimen (none 1.5%, ASA 1.3%, clopidogrel 0.9%, ASA/
clopidogrel 1.5%, P  .74). When analyzed by operation type, no difference in reoperation for bleeding was seen across
antiplatelet regimens. There was also no difference in the incidence of transfusion among antiplatelet treatment groups
(none 18%, ASA 17%, clopidogrel 0%, ASA/clopidogrel 24%, P  .1) and none when analyzed by individual operation
type. Among patients who did require transfusion, there was no significant difference in the mean number of units of
packed red blood cells required (none 0.7 units, ASA 0.5 units, clopidogrel 0 units, ASA/clopidogrel 0.6 units, P  .1)
or when stratified by operation type.
Conclusions: Patients undergoing peripheral arterial surgery in whom clopidogrel was continued either alone or as part of
dual antiplatelet therapy did not have significant bleeding complications compared with patients taking no antiplatelet
therapy or ASA alone at the time of surgery. These data suggest that clopidogrel can safely be continued preoperatively
in patients with appropriate indications for its use, such as symptomatic carotid disease or recent drug-eluting coronary
stents. ( J Vasc Surg 2011;54:779-84.)
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sSince the advent and subsequent approval of clopi-
dogrel (Plavix) by the Food and Drug Administration, its
use has become increasingly prevalent in contemporary
practice. Indications for clopidogrel therapy now include
acute coronary syndrome, myocardial infarction, stroke,
and peripheral vascular disease.1,2 Accordingly, clopi-
From the Section of Vascular Surgery, Dartmouth-Hitchcock Medical Cen-
ter, Lebanona; the Dartmouth Institute for Health Policy and Clinical
Practice, Center for Leadership and Improvement, Lebanonb; the Uni-
versity of Massachusetts Medical School, Worcesterc; and Fletcher Allen
Health Care, University of Vermont Medical School, Burlington.d
Competition of interest: none.
Presented at the Twenty-fourth Annual Meeting of the Eastern Vascular
Society, New York, NY, September 2010.
Reprint requests: David H. Stone, MD, Section of Vascular Surgery,
Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Leb-
anon, NH 03756 (e-mail: david.H.Stone@hitchcock.Org).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00s
Copyright © 2011 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2011.03.003ogrel now ranks among the most commonly prescribed
rescription medications and accounts for more than 5
illion dollars in annual pharmaceutical-derived reve-
ue.3
Because of its common use, vascular surgeons are
requently confronted with decision making around peri-
perative clopidogrel management. Several studies have
ocumented increased postoperative bleeding potential
nd transfusion requirements among clopidogrel-treated
atients undergoing cardiac surgery.1,4-7 Conversely,
lopidogrel cessation within 12 months following drug-
luting coronary stent implantation has been associated
ith adverse sequelae, including stent thrombosis and
nsuing myocardial infarction (MI).8-10 Interestingly,
here are few studies documenting the safety profile of
lopidogrel therapy at the time of carotid endarterec-
omy (CEA), even when performed in the context of
ymptomatic carotid occlusive disease.1 Moreover, such
tudies are small single-center experiences with limited
ample size that are likely underpowered to detect differ-
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bleeding.
In this setting, clinical debate persists surrounding the
optimal preoperative management of clopidogrel therapy.
Indeed, a recent published survey of European surgeons
demonstrated widespread variation in preoperative clopi-
dogrel management.11 While some surgeons favored clopi-
dogrel cessation at the time of surgery citing a perceived
increased risk of bleeding complications, others favored
continued perioperative therapy to prevent thrombosis.
The purpose of this study was to determine whether clopi-
dogrel was associated with significant bleeding complica-
tions measured by reoperation for bleeding and transfusion
requirement at the time of major peripheral arterial surgery.
METHODS
Subjects and database. This study reflects data col-
lected in the prospectively compiled registry of the Vascular
Study Group of New England (VSGNE).12 Over the study
interval from 2003 to 2009, patients were treated at 15
academic and community centers by 66 participating sur-
geons. Trained clinical data abstractors, nurses, and sur-
geons entered data prospectively for over 70 clinical, oper-
ative, and demographic variables for each procedure. All
analysts were blinded to patient, surgeon, and center iden-
tification.
Outcomes and variable definitions. Over the study
interval, preoperative clopidogrel or aspirin use defined as
being taken within 48 hours of surgery was recorded
among all patients undergoing CEA, lower extremity by-
pass (LEB), endovascular aneurysm repair (EVAR), and
open abdominal aortic aneurysm repair (oAAA) repair.
Ruptured AAAs were excluded from further analysis. The
primary endpoints of this study were postoperative bleed-
ing requiring reoperation (to determine a detrimental effect
of clopidogrel) and perioperative transfusion requirements,
defined as transfusion at the time of surgery or within the
index hospitalization. All endpoints were restricted to the
hospitalization for the respective surgery. In addition, total
transfusion requirements were assessed among clopidogrel-
treated and untreated patients who required transfusion
therapy. Perioperative transfusion is not recorded in the
VSG registry for CEA, in light of its associated infrequent
incidence.
Statistical analysis. Patient demographics were com-
pared using 2 analysis and t test for categorical and con-
tinuous variables, respectively. Reoperations for bleeding
and ongoing transfusion requirement were assessed among
patients using analysis of variance (ANOVA) and 2 (Fisher
exact correction). Wilcoxon rank-sum test was performed
to compare transfusion burden among patients who re-
ceived perioperative blood transfusion. The use of de-
identified data for this analysis was approved by the Insti-
tutional Review Board of Dartmouth Medical School.
RESULTS
Over the study interval, a total of 10,406 patients were
identified who underwent CEA (5264), LEB (2883), cVAR (1125), and oAAA repair (1134). Preoperative an-
iplatelet agent use among all patients varied with 19.3%
n  2010) taking no antiplatelet agents, 68.5% (n 
132) taking aspirin (ASA) alone, 2.2% (n  229) taking
lopidogrel alone, and 9.7% (n 1017) taking clopidogrel
nd ASA. Patients most likely to be on preoperative clopi-
ogrel (alone or as dual antiplatelet therapy) were those
ndergoing CEA, while this was least likely in the oAAA
roup (CEA 16.1%, LEB 9.0%, EVAR 6.5%, oAAA 5%)
Fig 1). Indications for clopidogrel use were unknown.
emographic details and comorbidities of all patients strat-
fied by antiplatelet regimen are depicted in the Table.
Reoperation for bleeding was not significantly different
mong patients based on antiplatelet regimen (none 1.5%,
SA 1.3%, clopidogrel 0.9%, ASA/clopidogrel 1.5%, P 
74). When analyzed by operation type, no difference in
eoperation for bleeding was seen across each respective
ntiplatelet regimen (Figs 2-5).
There was also no difference in the incidence of trans-
usion among antiplatelet treatment groups (none 18%,
SA 17%, clopidogrel 0%, ASA/clopidogrel 24%, P  .1).
his finding was also observed when patients were stratified
y operation for each antiplatelet regimen (LEB: none
8.8%, ASA 17.3%, clopidogrel 0%, ASA/clopidogrel
5.3%, P .12, EVAR: none 9.6%, ASA 9.6%, clopidogrel
%, ASA/clopidogrel 16%, P  .66, oAAA: none 37.8%,
SA 27.9%, clopidogrel 0%, ASA/clopidogrel 42.8%,
 .37).
Among patients who did require transfusion, there was
o significant difference in the mean number of units of
acked red blood cells required among the total study
ig 1. Antiplatelet use among patients undergoing carotid end-
rterectomy (CEA), lower extremity bypass (LEB), endovascular
bdominal aortic aneurysm repair (EVAR), and open AAA repair
oAAA). As depicted, clopidogrel use, either alone or as part of
ual antiplatelet therapy was most common among patients un-
ergoing CEA and least for oAAA. Transfusion data were not
ecorded for patients undergoing CEA given its clinical infrequent
ncidence.ohort (none 0.7 units, ASA 0.5 units, clopidogrel 0 units,
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by operation type, there was no statistical difference in the
mean number of units required among antiplatelet regi-
mens for each operation type (LEB: none 0.6 units, ASA
0.5 units, clopidogrel 0 units, ASA/clopidogrel 0.6 units,
P .14, EVAR: none 0.3 units, ASA 0.2 units, clopidogrel
Table. Comparison of patient demographics, comorbiditie
treatment groups
No antiplatelet
agent n/total (%) ASA only n/tot
Patient characteristics
Male gender 1353/2013 (67) 4720/7137
White race 1988/2011 (99) 7053/7128
Age
Less than 40 years 9/2013 (0.5) 10/7139
Age 40-49 84/2013 (4) 180/7139
Age 50-59 282/2013 (14) 947/7139
Age 60-69 535/2013 (27) 2205/7139
Age 70-79 733/2013 (36) 2682/7139
Age 80-89 349/2013 (17) 1069/7139
Age 90 or greater 21/2013 (1) 46/7139
Smoking (prior or
current) 1666/2010 (83) 5954/7130
Hypertension 1622/2013 (81) 6170/7134
Diabetes 654/2013 (32) 2341/7138
Beta blockers 1534/2011 (76) 6060/7135
Coronary disease 528/2012 (26) 2528/7135
CABG/PTCA 417/2012 (21) 2305/7136
Congestive heart
failure 209/2012 (10) 721/7137
COPD 640/2013 (32) 1953/7137
Dialysis 89/2013 (4) 161/7138
Creatinine 1.8% 201/1941 (10) 585/6959
Stress test
Not done 1188/1994 (60) 3959/7088
Normal result 607/1994 (30) 2171/7088
Abnormal result 199/1994 (10) 958/7088
Statin 979/2013 (49) 5087/7136
ASA, Aspirin;CABG, coronary artery bypass grafting;COPD, chronic obstru
Fig 2. Reoperation for bleeding among patients undergoing ca-
rotid endarterectomy (CEA), stratified by antiplatelet medication.0 units, ASA/clopidogrel 0.2 units, P  .7, oAAA: none c.4 units, ASA 0.8 units, clopidogrel NA, ASA/clopidogrel
.0 units, P  .18).
Estimated blood loss was recorded for patients under-
oing EVAR and oAAA repair, and this showed no signif-
cant differences among antiplatelet treatment regimens for
hese procedure types (EVAR: none 317mL, ASA 322mL,
d preoperative risk factors among antiplatelet
)
Clopidogrel only
n/total (%)
ASA and clopidogrel
n/total (%) P value
141/229 (62) 681/1016 (67) .338
224/228 (98) 1004/1014 (99) .757
0/229 (0) 1/1017 (0.1) .001
12/229 (5) 30/1017 (3)
27/229 (12) 163/1017 (16)
59/229 (26) 309/1017 (30)
89/229 (39) 370/1017 (36)
40/229 (17) 139/1017 (14)
2/229 (0.9) 5/1017 (0.5)
187/229 (82) 829/1012 (82) .532
199/229 (87) 921/1017 (91) .001
89/229 (39) 378/1017 (37) .010
181/229 (79) 896/1017 (88) .001
84/229 (37) 509/1015 (50) .001
76/228 (33) 485/1017 (48) .001
22/229 (10) 130/1017 (13) .071
66/229 (29) 305/1016 (30) .001
6/229 (3) 22/1017 (2) .001
25/223 (11) 75/988 (8) .014
135/228 (59) 627/1008 (62) .001
72/228 (32) 225/1008 (22)
21/228 (9) 156/1008 (15)
153/229 (67) 810/1016 (79) .001
ulmonary disease; PTCA, percutaneous transluminal coronary angioplasty.
ig 3. Reoperation for bleeding among patients undergoing ca-
otid endarterectomy (LEB), stratified by antiplatelet medication.s, an
al (%
(66)
(99)
(0.1)
(3)
(13)
(31)
(38)
(15)
(0.6)
(84)
(86)
(33)
(85)
(35)
(32)
(10)
(27)
(2)
(8)
(56)
(31)
(14)
(71)lopidogrel 585 mL, ASA/clopidogrel 282 mL, P  .66;
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September 2011782 Stone et aloAAA: none 1394 mL, ASA 1456 mL, clopidogrel 1955
mL, ASA/clopidogrel 1817 mL, P  .62.
DISCUSSION
This multi-institutional regional registry provides evi-
dence that preoperative clopidogrel, when taken alone or as
part of dual antiplatelet therapy, is not associated with
increased serious bleeding complications in a diverse group
of peripheral vascular operations. These findings have sig-
nificant implications for contemporary practice because
surgeons are now confronted with a growing percentage of
patients with extensive comorbidities such as symptomatic
carotid occlusive disease and coronary disease treated with
drug-eluting stents, who have an appropriate indication for
clopidogrel therapy.1,13,14
Based often on anecdotal experience, some surgeons
Fig 4. Reoperation for bleeding among patients undergoing en-
dovascular abdominal aortic aneurysm repair (EVAR), stratified by
antiplatelet medication.
Fig 5. Reoperation for bleeding among patients undergoing
open abdominal aortic aneurysm repair (oAAA), stratified by
antiplatelet medication.favor preoperative clopidogrel cessation, perceiving an in- ireased risk of bleeding complications, while others con-
inue clopidogrel to avoid perioperative thrombotic com-
lications, and this may vary by the type of planned
peration. A recent survey of 650 European vascular sur-
eons by Hamish et al depicts this variation in clinical
ractice among patients undergoing CEA.11 Specifically,
he authors report 43% and 55% of surgeons, respectively,
ould stop clopidogrel among symptomatic and asymp-
omatic patients undergoing CEA. Moreover, 49% and
7% of surveyed surgeons would favor clopidogrel cessa-
ion more than 7 days prior to CEA, for both symptomatic
nd asymptomatic patients.11 This demonstrates a clear
ack of consensus among practicing surgeons regarding
ptimal perioperative clopidogrel management even for
atients with a strong indication, such as those with symp-
omatic carotid disease undergoing CEA. Presumably for
perations with larger potential blood loss, such as oAAA
epair or LEB, the percentage of surgeons who would stop
lopidogrel treatment would be even higher.
In addition, the recent Clopidogrel and Acetylsalicylic
cid in Bypass Surgery for Peripheral Arterial Disease
CASPAR) trial, demonstrated that patients undergoing
elow-knee bypass showed no significant difference in se-
ere bleeding complications between clopidogrel vs
lacebo-treated groups.15 Interestingly, however, clopi-
ogrel therapy was initiated following a postoperative lag
eriod of 2 days to permit “complete” hemostasis, again,
resumably reflecting a perceived increased risk of bleeding
ssociated with preoperative clopidogrel use. It should be
ighlighted that the number of severe bleeding events were
mall in this trial, (n  9/426 [2.1%] clopidogrel vs n 
/422 [1.2%] placebo, P NS) potentially limiting defin-
tive conclusions. Severe bleeding was defined as per the
lobal Utilization of Streptokinase and Tissue Plasminogen
ctivator for Occluded Coronary Arteries (GUSTO) classifi-
ation,which included intracranial hemorrhage, and hemody-
amic compromise.16 In contrast, both mild (no transfu-
ion) (n  46/426 [10.8%] clopidogrel vs n  21/422
5.0%] placebo, P  .002) and moderate bleeding compli-
ations (transfusion but no hemodynamic compromise)
n  16/426 [3.8%] clopidogrel vs n  4/422 [0.9%]
lacebo, P  .007) were observed more commonly in the
lopidogrel-treated cohort compared with placebo, still
eaving some degree of ambiguity pertaining to this impor-
ant question.15
Studies of bleeding complications with clopidogrel at
he time of surgery have largely been single-center retro-
pective analyses with relatively small sample size focusing
n coronary artery bypass grafting (CABG) rather than
eripheral vascular surgery.4,5,17 In this regard, these stud-
es may be underpowered to detect a relatively low fre-
uency complication, and accordingly, remain limited in
heir ability to reach definitive conclusions.
Some opinion favoring preoperative clopidogrel cessa-
ion in vascular surgery appears to be extrapolated from
tudies documenting the impact of clopidogrel therapy at
he time of CABG. Indeed, Filsoufi et al reported both
ncreased transfusion requirements and all-cause mortality
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CABG.5 In concordance with these findings, Chu et al
demonstrated chest tube blood loss was significantly
greater in 312 clopidogrel-treated patients undergoing ur-
gent or emergent CABG. Moreover, mean total blood
product transfusions were also significantly higher among
clopidogrel-treated patients, as was the incidence of reop-
eration for bleeding.4 In contrast, Karabulut et al found no
significant differences in the incidence of reoperation for
bleeding, blood product transfusion, chest tube output, or
intensive care length of stay among 1628 patients under-
going CABG.17 Despite this larger overall sample size, only
48 patients constituted the treatment group on clopi-
dogrel, which may have impacted their conclusions.
Although there have been few studies of bleeding com-
plications associated with clopidogrel use in peripheral
arterial surgery, Fleming et al reported that clopidogrel-
treated patients could safely undergo CEA with no signifi-
cant difference in hematoma formation or blood loss be-
tween treated and untreated patients. However, the
authors’ conclusions reflect a sample size of 100 patients, in
whom only 19 had received preoperative clopidogrel treat-
ment.1
Our study, by comparison, demonstrates that preoper-
ative clopidogrel therapy is not associated with increased
bleeding complications measured by reoperation for bleed-
ing and blood transfusion across a diverse spectrum of
vascular surgical operations, including CEA, for which it is
most robustly powered, LEB, EVAR, and open aneurysm
repair (oAAA). Moreover, we demonstrate that among
patients who do require blood transfusion, there was no
difference in transfusion volume. These findings suggest that
surgeons can achieve sufficient hemostasis in clopidogrel-
treated patients during CEA, LEB, EVAR, and oAAA.
Moreover, these data would support the conclusion that
clopidogrel cessation prior to surgery is unnecessary when
managing patients with important indications for clopi-
dogrel use such as symptomatic carotid occlusive disease or
a previously placed drug-eluting coronary stent.
This observational study has several intrinsic limitations.
First, it is not a randomized comparison of clopidogrel-treated
vs untreated patients. Patients were treated and managed at
the discretion of the operating surgeon. In this regard, we are
unable to comment on the number of patients whomay have
had prior clopidogrel withheld prior to surgery. It is also
possible that a subset of patients had their antiplatelet medi-
cation discontinued within the half-life of the medication, yet
48 hours prior to surgery leading to unaccounted-for per-
sistent platelet dysfunction. However, one can speculate that
those surgeons, who would favor discontinuation of periop-
erative clopidogrel prior to surgery, would do so with an
adequate window to minimize this effect. Finally, although
concomitant use of perioperative anticoagulation use among
patients undergoing these types of operations is not common,
this is not captured in the VSGNE registry, which could
impact the primary endpoint.Despite not being a randomized
trial, this study is more robustly powered to detect differencesn low-frequency complications in a “real world” clinical ex-
erience reflecting both community and academic surgeons.
A second limitation is that the percentage of patients
aking clopidogrel either alone or in combination therapy
as low, especially in the bypass, EVAR, and oAAA groups.
hile this may limit our ability to reach definitive conclu-
ions, it still represents more than a fourfold larger experi-
nce of perioperative clopidogrel use than previously re-
orted. It should also be noted that the VSGNE registry
oes not record hematoma formation or surgical drain use,
hich may have disclosed differences in outcomes. Finally,
nly 4.7% (n  54) of patients undergoing oAAA received
reoperative clopidogrel treatment at the time of surgery.
onsequently, we do not believe that conclusions regard-
ng clopidogrel use at the time of oAAA should be drawn
ased on our experience. Accordingly, based on sample
ize, results reported herein are more robust for CEA, LEB,
nd EVAR, and least for oAAA repair, given the potential
or type II error in the latter group.
ONCLUSIONS
Based on our analysis of more than 10,000 patients
ndergoing a spectrum of major peripheral arterial opera-
ions, clopidogrel, either alone or as part of a dual antiplate-
et regimen, does not appear to be associated with serious
dverse bleeding complications, measured by reoperation
or bleeding or incidence of blood transfusion. Moreover,
here was no difference in transfusion volume among those
atients who did require transfusion. These data suggest
hat clopidogrel can be safely continued preoperatively in
atients with important indications for its use, such as
ymptomatic carotid disease or recent drug-eluting cardiac
tents.
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